Novavax Inc (NASDAQ: NVAX)

Novavax Inc. is a biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. The company leverages its proprietary recombinant nanoparticle vaccine technology and Matrix-M™ adjuvant platform to create immunogenic vaccine candidates. Its technology is applied to address global health challenges including COVID-19 influenza malaria and other infectious diseases. Novavax operates through strategic partnerships to advance its pipeline and expand access to its technologies.

Novavax generates revenue through product sales licensing agreements royalty payments and milestone payments from collaborations. The company sells its COVID-19 Vaccine (Nuvaxovid) under supply agreements with governments and organizations. It earns royalties and milestone payments from partners such as Sanofi Takeda Serum Institute of India and Pfizer for the use of its Matrix-M™ adjuvant and vaccine technology. Revenue is also recognized from technology transfer services and collaboration activities under licensing agreements.

The company operates through the following segments:

• Vaccines segment includes the development and commercialization of recombinant nanoparticle vaccines such as the COVID-19 Vaccine (Nuvaxovid) and investigational candidates for influenza malaria and other infectious diseases. This segment leverages Novavax’s proprietary antigen production technology using the baculovirus insect cell expression system to create protein-based nanoparticles.

• Adjuvant segment focuses on the proprietary Matrix-M™ saponin-based adjuvant which enhances immune response when combined with vaccine antigens. This segment involves the manufacturing of Matrix-M™ adjuvant at Novavax AB in Uppsala Sweden and through contract manufacturing arrangements. Revenue is generated through licensing the adjuvant to partners for use in their vaccine programs including malaria influenza and COVID-19 combinations.

Novavax holds a differentiated position in the vaccine industry due to its proprietary Matrix-M™ adjuvant and recombinant nanoparticle technology which together enable dose-sparing potent and durable immune responses. The company competes with major vaccine manufacturers such as Pfizer Moderna Sanofi GSK and Seqirus in the COVID-19 and seasonal influenza markets. Its competitive advantages include its ability to produce vaccines suitable for refrigerator temperature storage and its adjuvant’s potential to broaden applicability across infectious and non-infectious disease areas.

Novavax serves a diverse customer base including national governments global health organizations and pharmaceutical companies. Specific customers include the Commonwealth of Australia the Vaccine Alliance (Gavi) the Government of Canada Pharmac in New Zealand Takeda Pharmaceutical Company Limited Sanofi Pfizer and Serum Institute of India. The company also collaborates with research institutions such as the Jenner Institute at the University of Oxford on partner-led vaccine programs like the R21/Matrix-M™ adjuvant malaria vaccine.